<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; PowerShares Active Mega Cap</title>
	<atom:link href="http://www.stockbloghub.com/tag/powershares-active-mega-cap/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(EW) Edwards Lifesciences&#8217; Sapien Transcatheter Heart Valve on Way to Success</title>
		<link>http://www.stockbloghub.com/2011/04/09/ew-edwards-lifesciences-sapien-transcatheter-heart-valve-on-way-to-success/70636</link>
		<comments>http://www.stockbloghub.com/2011/04/09/ew-edwards-lifesciences-sapien-transcatheter-heart-valve-on-way-to-success/70636#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:28:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PMA]]></category>
		<category><![CDATA[PowerShares Active Mega Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70636</guid>
		<description><![CDATA[Recently, Edwards Lifesciences (EW) presented positive data for its Cohort A of the PARTNER trial at the American College of Cardiology annual conference in New Orleans. The PARTNER trial is evaluating Edwards’ Sapien transcatheter heart valve (THV) in both operable (Cohort A) and inoperable (Cohort B) patients with severe aortic stenosis. It was observed that the study achieved its primary endpoint after one year, indicating that survival of patients treated with Sapien was same as those who underwent open heart surgery. About 699 patients were included under Cohort A who were randomized equally for either high risk surgery or the Sapien THV. In case of Cohort B, 358 patients were randomized equally for medical management or the Sapien THV. Edwards submitted a pre-market approval (PMA) application for Cohort B to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/ew-edwards-lifesciences-sapien-transcatheter-heart-valve-on-way-to-success/70636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WMGI) Wright Medical Group Receives FDA Approval</title>
		<link>http://www.stockbloghub.com/2009/11/11/wmgi-wright-medical-group-receives-fda-approval/20297</link>
		<comments>http://www.stockbloghub.com/2009/11/11/wmgi-wright-medical-group-receives-fda-approval/20297#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:30:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PMA]]></category>
		<category><![CDATA[PowerShares Active Mega Cap]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20297</guid>
		<description><![CDATA[Wright Medical Group, Inc. (WMGI) recently received the Food and Drug administration (FDA) approval to market its CONSERVE Plus Total Hip Resurfacing System in the U.S. The new system, which has received FDA approval, provides surgeons with a bone-conserving alternative to traditional total hip replacement. With the FDA approval, Wright Medical can now market CONSERVE Plus in the original femoral and acetabular component configuration in the U.S. as specified in its PreMarket Approval (PMA) application with the FDA. The company also intends to develop additional enhancements to the system. Wright Medical is already marketing its CONSERVE Plus system, which has received FDA approval, with additional features in the international markets. The CONSERVE Plus system, which has received FDA approval, offers pain relief and restoration of normal hip functions while retaining  maximum ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/wmgi-wright-medical-group-receives-fda-approval/20297/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

